Healthcare · Biotechnology
Price
$2.26
Market Cap
$130.9M
Employees
32
Beta
1.46
Avg Volume
963,304
CEO
Esther Rajavelu
Business Description
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments. SPR720, an oral antibiotic targeting non-tuberculous mycobacterial (NTM) pulmonary disease. Spero Therapeutics has also forged several strategic alliances: A licensing agreement with Meiji Seika Pharma Co., Ltd. supports the ongoing development of tebipenem HBr. A separate licensing deal with Everest Medicines grants rights for the development, manufacturing, and commercialization of SPR206 across Greater China, South Korea, and various Southeast Asian nations. The company collaborates with the Bill & Melinda Gates Medical Research Institute to advance SPR720 for treating lung infections caused by Mycobacterium tuberculosis. Furthermore, a licensing agreement with Vertex Pharmaceuticals Incorporated covers patents associated with SPR720 and its active metabolite, SPR719. Founded in 2013, Spero Therapeutics maintains its corporate headquarters in Cambridge, Massachusetts.
Business History
Price Overview
Last updated: Jun 27, 2026 8:58am (just now)$2.26
+0.24 (+11.88%)
Day Range
$2.01 – $2.33
52-Week Range
$1.80 – $3.22
50-Day MA
$2.62
200-Day MA
$2.40
Volume
2,216,091.00
Share Structure
Outstanding
57,901,493.00
Float
46,522,113.00
Free Float
80.3%
High free float
— 80.3% of shares trade freely, ~19.7% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
APIStock Price / EPS (Diluted)
8.50
Stock Price: $2.26
EPS (Diluted): 0.15
EPS (Diluted): 0.15
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
2.21
Stock Price: $2.26
Total Equity: $59.02M
Shares: 59,039,225
Total Equity: $59.02M
Shares: 59,039,225
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
5.19
Market Cap: $130.86M
Total Debt: $1.96M
Cash: $40.27M
EBITDA: $8.83M
Total Debt: $1.96M
Cash: $40.27M
EBITDA: $8.83M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$93.2M
Market Cap: $130.86M
Total Debt: $1.96M
Cash: $40.27M
Total Debt: $1.96M
Cash: $40.27M
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
100.0%
Gross Profit: $59.62M
Revenue: $59.62M
Revenue: $59.62M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$24,000
Revenue: $59.62M
Revenue: $59.62M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
14.4%
Net Income: $8.57M
Revenue: $59.62M
Revenue: $59.62M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
35.6%
Net Income: $8.57M
Total Equity: $59.02M
Total Equity: $59.02M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
23.9%
Operating Income: -$24,000
Tax Rate: 3.0%
Equity: $59.02M
Total Debt: $1.96M
Cash: $40.27M
Tax Rate: 3.0%
Equity: $59.02M
Total Debt: $1.96M
Cash: $40.27M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
7.59
Current Assets: $67.29M
Current Liabilities: $8.87M
Current Liabilities: $8.87M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.03
Short-Term Debt: $1.96M
Long-Term Debt: $0.00
Total Debt: $1.96M
Total Equity: $59.02M
Long-Term Debt: $0.00
Total Debt: $1.96M
Total Equity: $59.02M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$1.01
Revenue: $59.62M
Shares: 59,039,225
Shares: 59,039,225
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$1.00
Total Equity: $59.02M
Shares: 59,039,225
Shares: 59,039,225
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-0.21
Operating CF: -$12.62M
CapEx: $0.00
Shares: 59,039,225
CapEx: $0.00
Shares: 59,039,225
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $2.26
Stock Price: $2.26
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $8.57M
Net Income: $8.57M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares SPRO against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 25, 2026 6:11pm (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $3.1M | $48.6M | $103.8M | $48.0M | $59.6M |
| Cost of Revenue | $0 | $0 | $51.4M | $96.8M | $0 |
| Gross Profit | $3.1M | $48.6M | $52.3M | -$48.8M | $59.6M |
| Operating Expenses | $91.0M | $90.8M | $30.9M | $24.6M | $59.6M |
| Operating Income | -$88.0M | -$42.2M | $21.5M | -$73.4M | $-24,000 |
| Net Income | -$89.8M | -$46.4M | $22.8M | -$68.6M | $8.6M |
| EBITDA | -$87.2M | -$42.9M | $27.2M | -$72.5M | $8.8M |
| EPS | $-2.91 | $-1.23 | $0.43 | $-1.27 | $0.15 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 25, 2026 6:11pm (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $112.6M | $109.1M | $76.3M | $52.9M | $40.3M |
| Total Current Assets | $157.9M | $109.1M | $131.2M | $107.3M | $67.3M |
| Total Assets | $171.1M | $124.8M | $182.4M | $110.5M | $68.9M |
| Current Liabilities | $18.7M | $21.6M | $37.2M | $49.1M | $8.9M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $82.8M | $48.9M | $75.5M | $64.4M | $9.9M |
| Total Equity | $88.3M | $75.9M | $106.9M | $46.1M | $59.0M |
| Retained Earnings | -$367.5M | -$413.9M | -$391.1M | -$459.6M | -$451.1M |
Cash Flow (Annual)
Last updated: Jun 25, 2026 6:11pm (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$64.3M | -$7.7M | -$33.0M | -$23.4M | -$12.6M |
| Capital Expenditure | $64.3M | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$64.3M | -$7.7M | -$33.0M | -$23.4M | -$12.6M |
| Acquisitions (net) | $39,000 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $27.4M | -$3.5M | -$32.8M | -$23.4M | -$12.6M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 8:58am (just now)| Metric | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| Revenue |
$800,000 $800,000 – $800,000
|
$3.2M $3.2M – $3.2M
|
$33.1M $33.1M – $33.1M
|
$99.1M $99.1M – $99.1M
|
| EBITDA |
$-395,861 $-395,861 – $-395,861
|
-$1.6M -$1.6M – -$1.6M
|
-$16.4M -$16.4M – -$16.4M
|
-$49.0M -$49.0M – -$49.0M
|
| Net Income |
-$17.1M -$17.1M – -$17.1M
|
$39.6M $39.6M – $39.6M
|
-$7.1M -$7.1M – -$7.1M
|
$44.3M $44.3M – $44.3M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 25, 2026 6:11pm (1d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +1,482.4% | +113.6% | -53.8% | +24.3% |
| Gross Profit Growth | +1,482.4% | +7.7% | -193.2% | +222.2% |
| Operating Income Growth | +52.0% | +150.9% | -441.5% | +100.0% |
| Net Income Growth | +48.3% | +149.1% | -400.6% | +112.5% |
| EBITDA Growth | +50.7% | +163.2% | -366.9% | +112.2% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-23 | Deshpande Milind | A-Award | 10,000.00 | $0.00 | $0 |
| 2026-06-23 | Deshpande Milind | A-Award | 20,000.00 | $2.15 | $43,000 |
| 2026-06-23 | Tregoning Kathleen | A-Award | 10,000.00 | $0.00 | $0 |
| 2026-06-23 | Tregoning Kathleen | A-Award | 20,000.00 | $2.15 | $43,000 |
| 2026-06-23 | Smith Cynthia | A-Award | 10,000.00 | $0.00 | $0 |
| 2026-06-23 | Smith Cynthia | A-Award | 20,000.00 | $2.15 | $43,000 |
| 2026-06-23 | VINK PATRICK V.J.J. | A-Award | 10,000.00 | $0.00 | $0 |
| 2026-06-23 | VINK PATRICK V.J.J. | A-Award | 20,000.00 | $2.15 | $43,000 |
| 2026-06-23 | THOMAS FRANK E | A-Award | 10,000.00 | $0.00 | $0 |
| 2026-06-23 | THOMAS FRANK E | A-Award | 20,000.00 | $2.15 | $43,000 |
| 2026-06-23 | Jackson Scott Thomas | A-Award | 10,000.00 | $0.00 | $0 |
| 2026-06-23 | Jackson Scott Thomas | A-Award | 20,000.00 | $2.15 | $43,000 |
| 2026-06-23 | Pottage John C Jr | A-Award | 10,000.00 | $0.00 | $0 |
| 2026-06-23 | Pottage John C Jr | A-Award | 20,000.00 | $2.15 | $43,000 |
| 2026-05-04 | Rajavelu Esther | S-Sale | 25,240.00 | $2.51 | $63,352 |
| 2026-02-06 | Rajavelu Esther | S-Sale | 37,101.00 | $2.36 | $87,558 |
| 2026-02-06 | Rajavelu Esther | S-Sale | 50,816.00 | $2.36 | $119,926 |
| 2026-02-06 | Keutzer Timothy | S-Sale | 18,652.00 | $2.36 | $44,019 |
| 2026-02-02 | Keutzer Timothy | A-Award | 68,000.00 | $0.00 | $0 |
| 2026-02-02 | Keutzer Timothy | S-Sale | 18,891.00 | $2.20 | $41,560 |
Dividend History (Last 20)
Last updated: Jun 25, 2026 6:11pm (1d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2015-09-16 | $0.02 | 2015-08-07 | 2015-09-18 | 2015-10-07 |
| 2015-06-17 | $0.02 | 2015-05-08 | 2015-06-19 | 2015-07-07 |
| 2015-03-18 | $0.02 | 2015-03-09 | 2015-03-20 | 2015-04-07 |
| 2014-12-17 | $0.02 | 2014-11-05 | 2014-12-19 | 2015-01-06 |
| 2014-09-17 | $0.02 | 2014-08-08 | 2014-09-19 | 2014-10-07 |
| 2014-06-18 | $0.02 | 2014-05-08 | 2014-06-20 | 2014-07-07 |
| 2014-03-19 | $0.02 | 2014-03-10 | 2014-03-21 | 2014-04-07 |
| 2013-12-17 | $0.02 | 2013-11-08 | 2013-12-19 | 2014-01-06 |
| 2013-09-17 | $0.02 | 2013-08-07 | 2013-09-19 | 2013-10-07 |
| 2013-06-12 | $0.02 | 2013-05-08 | 2013-06-14 | 2013-07-05 |
| 2013-03-20 | $0.02 | 2013-03-08 | 2013-03-22 | 2013-04-05 |
| 2012-12-17 | $0.01 | 2012-11-07 | 2013-01-07 | |
| 2012-09-17 | $0.01 | 2012-08-08 | 2012-10-05 | |
| 2012-06-13 | $0.01 | 2012-05-10 | 2012-07-06 | |
| 2012-03-20 | $0.01 | 2012-03-12 | 2012-04-04 | |
| 2011-12-12 | $0.01 | 2011-11-09 | 2012-01-05 | |
| 2011-09-14 | $0.01 | 2011-08-10 | 2011-10-05 | |
| 2011-06-13 | $0.01 | 2011-05-11 | 2011-07-08 | |
| 2011-03-22 | $0.01 | 2011-03-11 | 2011-04-04 | |
| 2010-12-13 | $0.01 | 2010-11-10 | 2010-12-31 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for SPRO — it's generated by the pipeline (
market-narrative step).
No community reviews yet for SPRO.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30